publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
preliminari
commun
antivir
activ
hepat
c
viru
hcv
sarsassoci
coronaviru
scv
studi
bioisoster
altern
scaffold
antivir
aryl
diketoacid
adk
use
two
arylmethyloxi
substitu
instal
thu
prepar
show
antihcv
activ
depend
aromat
substitu
moieti
deriv
also
activ
scv
addit
unlik
adk
show
select
inhibit
helicas
activ
scv
ntpasehelicas
activ
ntpase
helicas
activ
target
enzym
among
deriv
show
potent
activ
hcv
ec
mm
well
scv
ic
mm
atpas
activ
mm
helicas
activ
might
use
platform
structur
futur
develop
multitarget
broadspectrum
antivir
elsevi
masson
sa
right
reserv
aryl
diketoacid
adk
previous
identifi
inhibit
human
immunodefici
viru
integras
rnadepend
rna
polymeras
rdrp
hepat
c
viru
hcv
previou
commun
report
adk
arylmethyloxi
arylmethylamino
substitu
attach
aromat
ring
fig
inhibitor
hcv
rdrp
activ
well
ntpasehelicas
activ
sarsassoci
coronaviru
sarscov
scv
inhibit
two
differ
viral
enzym
hcv
rdrp
scv
ntpasehelicas
class
compound
noteworthi
novel
multitarget
broadspectrum
antivir
might
develop
structur
later
order
improv
unfavor
physicochem
well
pharmacokinet
properti
associ
diketoacid
moieti
bioisoster
replac
pharmacophor
diketoacid
core
structur
thick
line
fig
bhydroxyketon
moieti
thick
line
fig
scaffold
attempt
compar
adk
scaffold
provid
addit
advantag
side
central
bhydroxyketon
moieti
substitut
r
er
fig
allow
extens
structureeact
relationship
studi
recent
proofofconcept
studi
key
pharmacophor
arylmethyloxi
group
antivir
adk
introduc
opposit
side
core
structur
give
correspond
galangin
deriv
signific
antihcv
activ
observ
deriv
howev
unlik
adk
arylmethyloxi
substitu
show
inhibitori
activ
hcv
rdrp
scv
ntpasehelicas
galangin
deriv
lack
antiscv
activ
result
suggest
hcv
rdrp
might
bind
site
specif
scaffold
around
two
hydrophob
site
similar
shape
locat
also
assum
scv
ntpasehelicas
might
abl
accommod
group
galangin
scaffold
thu
order
confirm
rational
intend
use
instead
platform
structur
two
arylmethyloxi
substitu
attach
time
fig
howev
due
synthet
difficulti
associ
synthesi
flip
core
ac
ring
system
chromon
scaffold
introduc
substitu
enoleketo
arrang
flat
fuse
ac
ring
system
form
intramolecular
hydrogen
bond
believ
key
pharmacophor
element
flavon
well
chromon
fair
assum
flip
ac
ring
system
ketoeenol
form
ca
ring
system
would
affect
pharmacophor
chromon
scaffold
shown
fig
substitu
attach
flip
fuse
ring
system
superimpos
arylmethyloxi
substitu
fix
group
provid
deriv
potent
inhibitori
activ
hcv
rdrp
ic
mm
contrast
antihcv
activ
deriv
found
critic
depend
upon
size
posit
hydrophob
aromat
substitu
arylmethyloxi
group
aromat
substitu
group
vari
cl
cnat
aromat
ring
herein
report
synthesi
evalu
antihcv
well
antiscv
activ
novel
fig
synthesi
titl
compound
summar
scheme
follow
literatur
method
prepar
commerci
avail
due
intramolecular
hydrogen
bond
group
select
react
br
presenc
k
co
provid
alkyl
product
yield
treatment
lihmd
cs
mei
thf
provid
correspond
keten
dithioacet
cycliz
basic
condit
give
yield
sulfid
oxid
mcpba
whose
methylsulfonyl
group
success
displac
sodium
salt
various
substitut
benzyl
alcohol
furnish
deriv
yield
final
lewi
acidmedi
demethyl
necessit
care
control
reaction
condit
concurr
loss
arylmethyl
moieti
thu
optim
lewi
acid
well
reaction
condit
use
less
one
equival
alcl
ch
cl
found
method
choic
provid
desir
moder
yield
studi
combin
pharmacophor
arylmethyloxi
group
scaffold
prepar
deriv
synthes
deriv
evalu
antivir
activ
hcv
well
scv
result
summar
tabl
deriv
arylmethyloxi
substitu
show
moder
potent
antihcv
activ
compound
substitu
r
h
show
antihcv
activ
interestingli
compound
type
substitu
show
similar
antihcv
activ
regardless
posit
substitut
particular
deriv
bulki
iodo
substitu
ec
mm
significantli
activ
chlorin
ec
mm
cyano
ec
mm
substitut
one
line
observ
noteworthi
deriv
show
potent
antihcv
activ
ec
mm
compar
adk
ec
mm
taken
togeth
result
indic
critic
role
aromat
substitu
bind
deriv
viral
target
protein
propos
larg
hydrophob
bind
site
viral
target
protein
accommod
aromat
ring
bulki
substitu
hcv
rdrp
proven
viral
target
enzym
adk
also
assum
potenti
viral
target
protein
bioisoster
adk
includ
flavon
well
chromon
deriv
inhibitori
activ
synthes
deriv
hcv
genotyp
enzym
estim
enzym
activ
affect
addit
test
compound
data
shown
thu
antihcv
replicon
activ
deriv
could
attribut
differ
mechan
yet
determin
viral
helicas
coupl
energi
nucleotid
triphosph
ntp
hydrolysi
unwind
duplex
viral
nucleic
acid
due
critic
role
viral
viabil
ntpase
duplex
unwind
activ
subject
antivir
drug
discoveri
campaign
previou
studi
identifi
adk
antiscv
agent
select
inhibit
ic
mm
duplex
dnaunwind
helicas
activ
scv
ntpasehelicas
without
signific
impact
atpas
activ
tabl
unfortun
presum
due
presenc
addit
group
neither
two
deriv
show
antiscv
activ
tabl
thu
studi
scaffold
replac
two
arylmethyloxi
substitu
instal
result
deriv
show
interest
structureeact
relationship
first
comparison
adk
show
select
inhibit
helicas
activ
chromon
deriv
chloro
iodo
benzyloxi
substitu
inhibit
ntpase
helicas
activ
potent
inhibit
ntpase
activ
tabl
second
unlik
antihcv
activ
inhibitori
activ
scv
ntpasehelicas
depend
upon
posit
aromat
substitu
deriv
show
significantli
potent
activ
compar
correspond
congen
tabl
third
deriv
show
potent
antihcv
activ
among
seri
effect
inhibit
scv
ntpasehelicas
ic
mm
fourth
among
antiscv
one
show
potent
activ
ic
mm
atpas
activ
mm
helicas
activ
base
result
might
conclud
scv
ntpasehelicas
hydrophob
bind
region
specif
tabl
antihcv
activ
inhibit
scv
ntpasehelicas
cytotox
comparison
adk
aromat
ring
attach
core
structur
deriv
show
cytostat
effect
human
normal
fibroblast
cell
line
mm
tabl
structureeact
relationship
studi
adk
propos
deriv
two
arylmethyloxi
substitu
would
show
antivir
activ
hcv
scv
thu
prepar
show
antihcv
activ
cellbas
assay
anticip
depend
aromat
substitu
moieti
deriv
also
activ
scv
addit
unlik
adk
show
select
inhibit
helicas
activ
scv
ntpasehelicas
activ
ntpase
helicas
activ
target
enzym
among
show
potent
activ
hcv
ec
mm
well
scv
ic
mm
atpas
activ
mm
helicas
activ
absenc
structur
inform
scv
ntpasehelicas
result
would
provid
valuabl
inform
design
potent
inhibitor
also
antivir
agent
activ
hcv
scv
discov
studi
might
use
platform
structur
futur
develop
multitarget
broadspectrum
antivir
nuclear
magnet
reson
spectra
record
mhz
h
nmr
mhz
c
nmr
tetramethylsilan
intern
standard
chemic
shift
report
singlet
doublet
triplet
q
quartet
multiplet
br
broad
singlet
coupl
constant
report
hertz
hz
chemic
shift
report
part
per
million
rel
solvent
peak
test
compound
puriti
determin
revers
phase
hplc
hplc
perform
equip
variabl
wavelength
vw
uv
detector
e
mm
column
analyt
condit
follow
gradient
use
acetonitril
water
contain
formic
acid
min
acetonitril
water
contain
formic
acid
min
acetonitril
water
contain
formic
acid
min
acetonitril
water
contain
formic
acid
min
acetonitril
water
contain
formic
acid
min
acetonitril
water
contain
formic
acid
min
flow
rate
set
mlmin
uv
detect
two
differ
wavelength
nm
nm
solut
mg
mmol
k
co
mg
mmol
aceton
ml
slowli
ad
ml
mmol
reaction
mixtur
stir
h
c
cool
room
temperatur
filter
aceton
concentr
reduc
pressur
crude
product
purifi
column
chromatographi
silica
gel
hex
etoac
afford
mg
mmol
yield
yellow
oil
compound
mg
mmol
obtain
dissolv
thf
ml
result
solut
ad
stir
solut
lihmd
ml
mmol
thf
ml
min
c
min
cs
ml
mmol
ad
one
portion
reaction
mixtur
allow
warm
c
h
mei
ml
mmol
ad
dropwis
min
stir
continu
addit
h
room
temperatur
solut
aq
koh
ml
ad
reaction
mixtur
stir
c
min
reaction
mixtur
allow
cool
c
quench
addit
hcl
phase
separ
aqueou
phase
extract
ch
cl
three
time
combin
organ
layer
dri
mgso
concentr
reduc
pressur
crude
product
purifi
column
chromatographi
silica
gel
hex
etoac
stir
solut
mg
mmol
ch
cl
ml
ad
mcpba
mg
mmol
c
reaction
mixtur
stir
h
room
temperatur
wash
satur
aq
nahco
solut
dri
mgso
concentr
reduc
pressur
result
crude
product
purifi
column
chromatographi
silica
gel
hex
etoac
afford
mg
mmol
yield
procedur
describ
synthesi
repres
solut
mg
mmol
thf
ml
ad
nah
mg
mmol
bnoh
ml
mmol
c
mixtur
stir
h
room
temperatur
reaction
quench
hcl
extract
ch
cl
combin
organ
layer
dri
mgso
concentr
reduc
pressur
crude
compound
purifi
column
chromatographi
silica
gel
hex
etoac
afford
mg
mmol
yield
white
powder
synthesi
reaction
bnoh
mg
mmol
mg
mmol
accord
procedur
describ
afford
mg
mmol
yield
white
powder
procedur
describ
synthesi
repres
solut
mg
mmol
ch
cl
ml
ad
alcl
mg
mmol
c
mixtur
stir
h
room
temperatur
reaction
quench
hcl
extract
etoac
dri
mgso
concentr
reduc
pressur
crude
compound
purifi
column
chromatographi
silica
gel
hex
etoac
mc
afford
synthesi
desir
compound
mg
reaction
mg
mmol
alcl
mg
mmol
accord
procedur
describ
synthesi
afford
mg
mmol
yield
white
